17/04/2025
Change in Project Coordinator from Amniotics to Magle Biopharma
In October 2024, Magle Group completed a merger with Amniotics. Since then, Magle Group has continued Amniotics’ business operations in the company Magle Biopharma, which is part of the Magle Group suite of companies. Magle Biopharma has become the new project coordinator for the project, with Magle Chemoswed Holding registered as an associate company.
Read more about Magle Group
24/08/2023
Tumor stem cells hide in the body and cause patients with aggressive cancers to often relapse. By programming genetically modified killer cells to “vacuum” up the remaining tumor stem cells, it is hoped to find more effective treatment options. The international research project led by Lund University has now been awarded 40 million by Horizon Europe, to tailor immunotherapy for AML, glioblastoma and pancreatic cancer.